|
|
|
|
|
|
|
|
|
|
|
30.05.25 - 14:48
|
Abeona Therapeutics® to Present at the Jefferies Global Healthcare Conference (GlobeNewswire EN)
|
|
|
CLEVELAND, May 30, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that Vish Seshadri, Ph.D., Chief Executive Officer, and Madhav Vasanthavada, Ph.D., Chief Commercial Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 4, 2025 at 11:40 a.m. Eastern Time....
|
|
|
|
|
|
|
|
|
12.05.25 - 13:33
|
Abeona Therapeutics® Enters into Agreement to Sell Priority Review Voucher for $155 Million (GlobeNewswire EN)
|
|
|
CLEVELAND, May 12, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has entered into a definitive asset purchase agreement to sell its Rare Pediatric Disease Priority Review Voucher (PRV) for gross proceeds of $155 million upon the closing of the transaction. Abeona was awarded the PRV following the U.S. Food and Drug Administration (FDA) approval of ZEVASKYN™ (prademagene zamikeracel) on April 28, 2025....
|
|
|
|
|
01.05.25 - 04:12
|
FDA Approves First Cell-Based Gene Therapy For Rare Skin Disorder (ZeroHedge)
|
|
|
FDA Approves First Cell-Based Gene Therapy For Rare Skin Disorder
Authored by Zachary Stieber via The Epoch Times (emphasis ours),
The Food and Drug Administration (FDA) has approved Zevaskyn, a gene therapy for a rare skin disorder, the company that makes the product said on April 29.
The U.S. Food and Drug Administration building in White Oak, Md., on June 5, 2023. Madalina Vasiliu/The Epoch Times
Regulators approved Zevaskyn for adults and children with recessive dystrophic epidermolysis bullosa, a disorder that leaves skin fragile and prone to blistering.
Severe cases of the disorder can result in loss of vision and other serious medical issues, according to the National Library of Medicine.
Recessive dystrophic epidermolysis bullosa has no cure.
Zevaskyn is the first cell-based gene therapy to receive approval for the condition. Abeona Therapeutics, which makes the therapy, said it only requires one application.
“Through a single surgical application, Zevaskyn can now offer people with ...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
